MedDataX Logo

Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline

NCT ID: NCT00343122

Last Updated: 2007-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. Its diagnosis is established via contrast enhanced echocardiography. One used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. The purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

echocardiography for intrapulmonary vasodilatation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* presence of liver cirrhosis
* evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt

Exclusion Criteria

* inadequate echocardiographic image quality
* allergies to echocardiographic contrast agents
* pulmonary valve stenosis
* pulmonary embolism
* relevant tricuspid regurgitation
* cardiomyopathy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Schenk, MD

Role: PRINCIPAL_INVESTIGATOR

Intensive Care Unit 13h1, Dep. of Internal Medicine IV, Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Intensive Care Unit 13H1, Dep. of Internal Medicine IV, Medical University of Vienna

Vienna, Vienna, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Valentin Fuhrmann, MD

Role: CONTACT

[email protected]
0043-1-40400 ext. 4766

Peter Schenk, MD

Role: CONTACT

0043-1-40400 ext. 4766

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Valentin Fuhrmann, MD

Role: primary

[email protected]
0043-1-40400 ext. 4766

References

Explore related publications, articles, or registry entries linked to this study.

Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004 Nov;24(5):861-80. doi: 10.1183/09031936.04.00010904. No abstract available.

Reference Type BACKGROUND
PMID: 15516683 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 4462005

Identifier Type: -

Identifier Source: org_study_id